Impact of estrogen receptor expression level on response to neoadjuvant chemotherapy and prognosis in HER2-negative breast cancers

Impact of estrogen receptor expression level on response to neoadjuvant chemotherapy and prognosis in HER2-negative breast cancers

Abstract Background Breast cancers with 1–10% cell staining for estrogen receptor (ER) present particular clinical features. The clinical data of estrogen receptor expression level and treatment effect are limited, particularly regarding chemotherapy benefit. We evaluated the pathologic response to...

Podrobná bibliografie
Hlavní autoři:	Hai-long Chen, Feng-bo Huang, Qiang Chen, Yong-chuan Deng
Médium:	Článek
Jazyk:	English
Vydáno:	BMC 2023-09-01
Edice:	BMC Cancer
Témata:	Breast cancer Estrogen receptor Neoadjuvant chemotherapy Pathologic complete response Prognosis
On-line přístup:	https://doi.org/10.1186/s12885-023-11368-2

Podobné jednotky

Estrogen receptor-negative/progesterone receptor-positive breast cancer has distinct characteristics and pathologic complete response rate after neoadjuvant chemotherapy
Autor: He Dou, a další
Vydáno: (2024-01-01)

Neoadjuvant chemotherapy with trastuzumab in HER2-positive breast cancer: pathologic complete response rate, predictive and prognostic factors
Autor: I.P.C. Buzatto, a další

Predictive factors for outcome in HER2-low breast cancer patients after neoadjuvant chemotherapy
Autor: Yingbo Shao, a další
Vydáno: (2025-03-01)

Clinicopathological characteristics and value of HER2-low expression evolution in breast cancer receiving neoadjuvant chemotherapy
Autor: Yingbo Shao, a další
Vydáno: (2024-02-01)

Utility of 18F-FDG PET/CT for predicting pathologic complete response in hormone receptor-positive, HER2-negative breast cancer patients receiving neoadjuvant chemotherapy
Autor: In Hee Lee, a další
Vydáno: (2020-11-01)

Association of tumor‐infiltrating lymphocytes before and after neoadjuvant chemotherapy with pathological complete response and prognosis in patients with breast cancer
Autor: Jin Hong, a další
Vydáno: (2021-11-01)

Prognosis and influencing factors of ER-positive, HER2-low breast cancer patients with residual disease after neoadjuvant chemotherapy: a retrospective study
Autor: Lingfeng Tang, a další
Vydáno: (2024-05-01)

A real-world clinicopathological model for predicting pathological complete response to neoadjuvant chemotherapy in breast cancer
Autor: Shan Fang, a další
Vydáno: (2024-02-01)

Efficacy and prognosis of HER2-Low and HER2-Zero in triple-negative breast cancer after neoadjuvant chemotherapy
Autor: Zhendong Shi, a další
Vydáno: (2024-07-01)

Pathological complete response following neoadjuvant chemotherapy for locally advanced intrahepatic cholangiocarcinoma
Autor: Yoshitaka Shimamaki, a další
Vydáno: (2024-02-01)

Pathological complete response to neoadjuvant chemotherapy in triple negative breast cancer – single hospital experience
Autor: Elina Sivina, a další
Vydáno: (2023-03-01)

Comparison of clinicopathological characteristics and response to neoadjuvant chemotherapy between HER2-low and HER2-zero breast cancer
Autor: Shuling Zhou, a další
Vydáno: (2023-02-01)

Biomarker Alteration after Neoadjuvant Endocrine Therapy or Chemotherapy in Estrogen Receptor-Positive Breast Cancer
Autor: Mengping Long, a další
Vydáno: (2022-12-01)

Correlation of an immune-related 8-gene panel with pathologic response to neoadjuvant chemotherapy in patients with primary breast cancers
Autor: Ling-Ming Tseng, a další
Vydáno: (2023-12-01)

Metabolic syndrome is a risk factor for breast cancer patients receiving neoadjuvant chemotherapy: A case-control study
Autor: Zhaoyue Zhou, a další
Vydáno: (2023-01-01)

Survival outcomes of locally advanced gastric cancer cases with pathological complete response received neoadjuvant chemotherapy
Autor: Qing Hu, a další
Vydáno: (2021-06-01)

The implications of a pathological complete response of the primary tumour after neoadjuvant chemotherapy for breast cancer on axillary surgery
Autor: Mina M. G. Youssef, a další
Vydáno: (2021-02-01)

Short- and long-term outcomes of neoadjuvant chemotherapy compared with neoadjuvant chemoradiotherapy for locally advanced rectal cancer: an updated meta-analysis
Autor: Yue Guo, a další
Vydáno: (2025-02-01)

Axillary Lymph Node Dissection Rates and Prognosis From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Pre-Menopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer
Autor: Sungchan Gwark, a další
Vydáno: (2021-09-01)

Network-based approach to identify biomarkers predicting response and prognosis for HER2-negative breast cancer treatment with taxane-anthracycline neoadjuvant chemotherapy
Autor: Cui Jiang, a další
Vydáno: (2019-09-01)

PROACTING: predicting pathological complete response to neoadjuvant chemotherapy in breast cancer from routine diagnostic histopathology biopsies with deep learning
Autor: Witali Aswolinskiy, a další
Vydáno: (2023-11-01)

Factors predicting pathological complete response to neoadjuvant chemotherapy in patients diagnosed with non-metastatic muscle invasive urothelial bladder cancer
Autor: Zuhat Urakçı, a další
Vydáno: (2023-10-01)

Markers Associated With Tumor Recurrence in Patients With Breast Cancer Achieving a Pathologic Complete Response After Neoadjuvant Chemotherapy
Autor: Li-Yun Xie, a další
Vydáno: (2022-04-01)

Efficacy evaluation of neoadjuvant chemotherapy in patients with HER2-low expression breast cancer: A real-world retrospective study
Autor: Lingfeng Tang, a další
Vydáno: (2022-12-01)

SDF-1 expression and tumor-infiltrating lymphocytes identify clinical subtypes of triple-negative breast cancer with different responses to neoadjuvant chemotherapy and survival
Autor: Ruo-Xi Wang, a další
Vydáno: (2022-10-01)

Association of Pathologic Complete Response and Long-Term Survival Outcomes Among Patients Treated With Neoadjuvant Chemotherapy or Chemoradiotherapy for NSCLC: A Meta-Analysis
Autor: Samuel Rosner, MD, a další
Vydáno: (2022-09-01)

Imaging‐proteomic analysis for prediction of neoadjuvant chemotherapy responses in patients with breast cancer
Autor: Jingxian Duan, a další
Vydáno: (2023-12-01)

Anaemia and pathologic complete response rate according to carboplatin dose in HER2+ breast cancer treated with neoadjuvant TCHP
Autor: Jung Hwan Ji, a další
Vydáno: (2023-01-01)

Neoadjuvant chemotherapy efficacy and prognosis in HER2-low and HER2-zero breast cancer patients by HR status: a retrospective study in China
Autor: Shaorong Zhao, a další
Vydáno: (2024-05-01)

Pretreatment Systemic Immune-Inflammation Index Can Predict Response to Neoadjuvant Chemotherapy in Cervical Cancer at Stages IB2-IIB
Autor: Pingping Liu, a další
Vydáno: (2022-04-01)

Accuracy of core biopsy image-guided post-neoadjuvant chemotherapy breast to predict pathologic complete response
Autor: P. V. Krivorotko, a další
Vydáno: (2022-12-01)

Response rate and clinical outcome of HER2-low breast cancer after neoadjuvant therapy: a single-center retrospective study
Autor: WANG Ruoxi, JI Peng, GONG Yue, CHEN Sheng
Vydáno: (2023-07-01)

An Immune-Associated Genomic Signature Effectively Predicts Pathologic Complete Response to Neoadjuvant Paclitaxel and Anthracycline-Based Chemotherapy in Breast Cancer
Autor: Changfang Fu, a další
Vydáno: (2021-08-01)

A Qualitative Transcriptional Signature for Predicting Extreme Resistance of ER-Negative Breast Cancer to Paclitaxel, Doxorubicin, and Cyclophosphamide Neoadjuvant Chemotherapy
Autor: Yanhua Chen, a další
Vydáno: (2020-03-01)

A nomogram for predicting pathologic node negativity after neoadjuvant chemotherapy in breast cancer patients: a nationwide, multicenter retrospective cohort study (CSBrS-012)
Autor: Amina Maimaitiaili, a další
Vydáno: (2024-05-01)

Estrogen Receptor and Claudin-6 Might Play Vital Roles for Long-Term Prognosis in Patients With Luminal A Breast Cancer Who Underwent Neoadjuvant Chemotherapy
Autor: Yushi Liu, a další
Vydáno: (2022-06-01)

Construction of a nomogram prediction model for the pathological complete response after neoadjuvant chemotherapy in breast cancer: a study based on ultrasound and clinicopathological features
Autor: Pingjuan Ni, a další
Vydáno: (2025-03-01)

Optimal Choice of Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer: Clinical Insights
Autor: Lucas MW, a další
Vydáno: (2022-08-01)

Predicting the efficacy of neoadjuvant chemotherapy in breast cancer patients based on ultrasound longitudinal temporal depth network fusion model
Autor: Xiaodan Feng, a další
Vydáno: (2025-02-01)

Are baseline ultrasound and mammographic features associated with rates of pathological completes response in patients receiving neoadjuvant chemotherapy for breast cancer?
Autor: Sarah L. Savaridas, a další
Vydáno: (2019-10-01)